PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Papaverine→

Papaverine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
58-74-2
Molecular formula
C20H21NO4
Molecular weight
339.4 g/mol
Drug class
Benzylisoquinoline alkaloiddirect-acting smooth-muscle relaxant and vasodilator
Mechanism of action
The precise mechanism is not completely established. Papaverine appears to inhibit multiple phosphodiesterase isoenzymes, increase intracellular cyclic nucleotide signalling and may also directly inhibit calcium channels, relaxing vascular and visceral smooth muscle.
Indications / reported uses
  • Treatment of selected smooth-muscle spasm or vasospastic conditions with formulations and routes authorised in the relevant jurisdiction.
  • Intracavernosal use for erectile dysfunction has been described in specialist practice but should not be interpreted as a universal approved indication.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68010208 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/papaverine-hydrochloride

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Papaverine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Papaverine Permitted Daily Exposure (PDE) report (the Papaverine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Papaverine Occupational Exposure Limit (OEL) report (the Papaverine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.